BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.2%

Neg 0% Neu 86.2% Pos 0%

BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.

Comments

No comments yet. Be the first!